ARKG - ETF AI Analysis
Top Page
ARK Genomic Revolution ETF (ARKG)
Rating:52Neutral
Price Target:―
Positive Factors
Strong Recent Short-Term Rebound
The ETF has shown strong gains over the past month, suggesting renewed investor interest after recent weakness.
Leading Genomics Holdings
Several top positions, including companies focused on gene editing and sequencing, have delivered strong year-to-date performance that supports the fund’s overall returns.
Focused Exposure to Genomic Innovation
The portfolio is heavily tilted toward health care companies at the forefront of genomic research, giving investors targeted access to a high-growth theme.
Negative Factors
High Expense Ratio
The fund’s relatively high fee means more of the investment return goes to costs compared with lower-cost ETFs.
Concentrated Top Holdings
A small number of stocks make up a large share of the portfolio, so poor performance in just a few names can significantly hurt the ETF.
Narrow Sector and Geographic Focus
With most assets in U.S. health care and genomics companies, the fund offers limited diversification across sectors and regions, increasing sensitivity to downturns in this niche area.
ARKG vs. SPDR S&P 500 ETF (SPY)
AUM1.68B
RegionGlobal
Expense Ratio0.75%
Beta1.66
IssuerARK
Inception DateOct 31, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,423,686
30 Day Avg. Volume3,143,515
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
48.86Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ARKG Summary
ARK Genomic Revolution ETF (ARKG) is a thematic fund that focuses on companies working in genetics and DNA technology, mainly in the U.S. health care sector. It does not track a traditional index but is actively managed to invest in areas like gene editing, DNA sequencing, and advanced medical testing. Well-known holdings include Illumina and Crispr Therapeutics. Someone might invest in ARKG for long-term growth potential from breakthroughs in medicine and biotechnology. However, this ETF is concentrated in a risky, fast-changing sector, so its price can be very volatile and may go up and down more than the overall market.
How much will it cost me?The ARK Genomic Revolution ETF (ARKG) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, allowing it to focus on innovative companies in the fast-evolving genomics sector.
What would affect this ETF?The ARK Genomic Revolution ETF (ARKG) could benefit from continued advancements in genomic technologies like CRISPR and bioinformatics, as well as increased global investment in healthcare innovation. However, it may face challenges from regulatory hurdles in biotechnology, potential economic downturns affecting funding for research, and competition within the healthcare sector. Its global exposure and focus on cutting-edge companies provide growth potential, but also come with risks tied to market volatility and the success of its top holdings.
ARKG Top 10 Holdings
ARKG is leaning hard into the genomic revolution, with a tight cluster of high‑beta health care names steering the ship. Twist Bioscience and AbSci have been rising sharply, giving the fund a strong tailwind, while 10x Genomics and Illumina add steady, more established exposure to DNA sequencing and lab tools. On the flip side, Tempus AI has been lagging, and Crispr Therapeutics looks mixed, occasionally losing steam. Overall, this is a highly concentrated, globally focused bet on cutting‑edge biotech rather than a broad, balanced stock basket.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Twist Bioscience | 8.39% | $141.45M | $5.45B | 141.07% | 43 Neutral | |
| Tempus AI, Inc. Class A | 7.79% | $131.23M | $9.13B | -27.11% | 52 Neutral | |
| Crispr Therapeutics AG | 7.08% | $119.35M | $5.22B | 19.34% | 40 Underperform | |
| 10x Genomics | 6.98% | $117.59M | $4.41B | 205.28% | 60 Neutral | |
| AbSci | 6.82% | $114.91M | $1.16B | 204.35% | 49 Neutral | |
| Personalis | 6.16% | $103.78M | $1.10B | 63.77% | 49 Neutral | |
| Guardant Health | 4.70% | $79.19M | $17.47B | 165.36% | 61 Neutral | |
| Beam Therapeutics | 4.31% | $72.67M | $3.51B | 112.63% | 58 Neutral | |
| Illumina | 4.18% | $70.45M | $24.50B | 78.10% | 71 Outperform | |
| Natera | 4.14% | $69.75M | $33.14B | 34.30% | 73 Outperform |
ARKG Technical Analysis
Positive
―
Price Trends
33.20
Positive
30.66
Positive
30.33
Positive
Market Momentum
2.78
Negative
78.00
Negative
90.31
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ARKG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 37.04, equal to the 50-day MA of 33.20, and equal to the 200-day MA of 30.33, indicating a bullish trend. The MACD of 2.78 indicates Negative momentum. The RSI at 78.00 is Negative, neither overbought nor oversold. The STOCH value of 90.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARKG.
ARKG Peer Comparison
Comparison Results
Performance Comparison
ARKG
ARK Genomic Revolution ETF
42.91
18.56
76.22%
ARKK
Ark Innovation Etf
―
―
―
FWD
AB Disruptors ETF
―
―
―
ARKQ
ARK Autonomous Technology & Robotics ETF
―
―
―
ARKW
ARK Next Generation Internet ETF
―
―
―
SQS
Sapient Quality Select ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents